Location: Home > Scientists
  Scientists
Name:
 Jinyong Wang
Subject:
 Blood & Immune Cell Regeneration
Tel/Fax:
 +86-10-64808780  / 
E-mail:
 wangjinyong@ioz.ac.cn
Address:
 1 Beichen West Road, Chaoyang District, Beijing 100101, P.R.China
More:
 Group of Blood & Immune Cell Regeneration      
Resume:

Dr. Jinyong Wang is the Principal Investigator of the Blood & Immune Cell Regeneration research group at the Institute of Zoology, Chinese Academy of Sciences, and he is a full professor at the University of Chinese Academy of Sciences. He is a chief scientist of the National Key Research and Development Program of China in stem cell field, a receiver of the National Natural Science Foundation for Distinguished Young Scholars from NSFC. His research group are committed to testing new theories and developing new technologies for blood and immune cell regeneration from pluripotent stem cells, and the clinical transformation of new cell products. Representative contributions from his research findings include: Directing T lymphopoiesis, B lymphopoiesis, and multi-lineage hematopoiesis from pluripotent stem cells by defined transcription factors; reprograming B cells into functional T cells in vivo by a single transcription factor Hoxb5. The above observations support the theory that the fate decision of blood and immune lineages can be manipulated by transcription factors starting from an early developing stage prior to the occurrence of hematopoietic cells. Moreover, his group developed an efficient method of NK cell regeneration from human pluripotent stem cells based on lateral plate mesoderm cell-formed organoid aggregates, which is 100 times more efficient than traditional EB approach. Using this method, the generated NK cell product (JK500 cell injection) has been assessed in IIT (Gov clinical trial registration number: NCT05519384).

 

Biography

2021.06 – now: Institute of Zoology, Chinese Academy of Sciences/ Principal Investigator

2012.03 – 2021.05: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences/ Principal Investigator

2007.09 – 2012.02: Wisconsin Medical College, University of Wisconsin-Madison/Postdoc Fellow

2006.08 – 2007.08: Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences/Postdoc Fellow

2001.09 – 2006.07: Zhejiang University/Ph.D

1997.09 – 2001.07: Qingdao Agricultural University (Laiyang Agricultural College)/Bachelor

Research Interests:

Blood & Immune Cell Regeneration

1. Pluripotent Stem cell and hematopoietic stem/progenitor cell regeneration

Based on the lineage differentiation principle of pluripotent stem cells (ESC/iPSC) and gene editing technique, transplantable hematopoietic stem/progenitor cells are induced from PSCs, to explore alternative cell sources for traditional bone marrow transplantation, and to achieve the purpose of treating tumors, genetic diseases, viral infections, organ degeneration and senescence, pathological inflammation, etc.

2. Pluripotent stem cells and immune cell regeneration (T, B, NK and other immune cells)

Based on the lineage differentiation principle of pluripotent stem cells (ESC/iPSC) and gene editing approaches, we successfully obtained transplantable lymphocyte progenitors, which gave rise to functional terminal B, T, and NK lymphocytes in vivo after transplantation. The derived cell products are and will be evaluated in clinical trials for treating related diseases.

Awards and Honors:

Professional Activities:

Research Grants:

Selected Publications:
  1. Lin, Y., Z. Xiao, F. Hu, X. Zheng, C. Zhang, Y. Wang, Y. Liu, D. Huang, Z. Wang, C. Xia, Q. Weng, L. Zhang, Y. Zhao, H. Qi, Y. Shen, Y. Chen, F. Zhang, J. Wu, P. Liu, J. Xu, L. Liu, Y. Zhu, J. Zhang, W. Qian, A. Liang, X. Zhu, T. Wang, M. Zhang and J. Wang (2025). "Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies." J Hematol Oncol 18(1): 57.
  2. Zhang, Q., C. Xia, Q. Weng, L. Zhang, Y. Wang, Y. Liu, X. Zheng, Y. Lin, Y. Chen, Y. Shen, H. Qi, L. Liu, Y. Zhu, M. Zhang, D. Huang, F. Hu, M. Zhang, H. Zeng, J. Wang and T. Wang (2024). "Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals." Front Immunol 15: 1504459.
  3. Liu, Y., M. Zhang, X. Shen, C. Xia, F. Hu, D. Huang, Q. Weng, Q. Zhang, L. Liu, Y. Zhu, L. Wang, J. Hao, M. Zhang, T. Wang and J. Wang (2024). "Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals." Cell Prolif: e13727.
  4. Wang, Y., J. Li, Z. Wang, Y. Liu, T. Wang, M. Zhang, C. Xia, F. Zhang, D. Huang, L. Zhang, Y. Zhao, L. Liu, Y. Zhu, H. Qi, X. Zhu, W. Qian, F. Hu and J. Wang (2024). "Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity." Cell Prolif: e13683.
  5. Peng, H., Y. Lin, F. Hu, C. Lv, B. Wu, Q. Weng, L. Liu, C. Xia, X. Liu, Y. Zhao, Q. Zhang, Y. Geng, M. Zhang and J. Wang (2023). "Prolonged generation of multi-lineage blood cells in wild-type animals from pluripotent stem cells." Stem Cell Reports 18(3): 720-735.
  6. Wu, B., Q. Zhang, P. Hong, L. Liu, H. Peng, C. Xia, T. Wang, Y. Wang, Q. Weng, X. Liu, Y. Geng, J. Wang and H. Wu (2023). "Antigen-specific TCR-T cells from Rag2 gene-deleted pluripotent stem cells impede solid tumour growth in a mouse model." Cell Prolif: e13389.
  7. Xiong, J., Y. Zhao, Y. Lin, L. Chen, Q. Weng, C. Shi, X. Liu, Y. Geng, L. Liu, J. Wang and M. Zhang (2022). "Identification and characterization of innate lymphoid cells generated from pluripotent stem cells." Cell Rep 41(5): 111569.
  8. Huang, D., J. Li, F. Hu, C. Xia, Q. Weng, T. Wang, H. Peng, B. Wu, H. Wu, J. Xiong, Y. Lin, Y. Wang, Q. Zhang, X. Liu, L. Liu, X. Zheng, Y. Geng, X. Du, X. Zhu, L. Wang, J. Hao and J. Wang (2022). "Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells." Cell Discov 8(1): 121.
  9. Huang, D., Q. Zhao, M. Zhang, Q. Weng, Q. Zhang, K. Wang, F. Dong, H. Cheng, F. Hu and J. Wang (2022). "Hoxb5 reprogrammes murine multipotent blood progenitors into haematopoietic stem cell-like cells." Cell Prolif 55(6): e13235.
  10. Yu, B., B. Wu, P. Hong, H. Peng, M. Zhang, Q. Zhang, L. Liu, X. Liu, Y. Geng, J. Wang and Y. Lan (2022). "Co-Expression of Runx1, Hoxa9, Hlf, and Hoxa7 Confers Multi-Lineage Potential on Hematopoietic Progenitors Derived From Pluripotent Stem Cells." Front Cell Dev Biol 10: 859769.
  11. Zhang, Q., B. Wu, Q. Weng, F. Hu, Y. Lin, C. Xia, H. Peng, Y. Wang, X. Liu, L. Liu, J. Xiong, Y. Geng, Y. Zhao, M. Zhang, J. Du and J. Wang (2022). "Regeneration of immunocompetent B lymphopoiesis from pluripotent stem cells guided by transcription factors." Cell Mol Immunol 19(4): 492-503.
  12. Wang, T., C. Xia, Q. Weng, K. Wang, Y. Dong, S. Hao, F. Dong, X. Liu, L. Liu, Y. Geng, Y. Guan, J. Du, T. Cheng, H. Cheng and J. Wang (2022). "Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway." Haematologica 107(1): 154-166.
  13. Zhou, P., C. Xia, T. Wang, Y. Dong, Q. Weng, X. Liu, Y. Geng, J. Wang and J. Du (2021). "Senescent bone marrow microenvironment promotes Nras-mutant leukemia." J Mol Cell Biol 13(1): 72-74.
  14. Lv, C., S. Chen, F. Hu, D. Huang, T. Wang, J. Du, J. Wang and H. Wu (2021). "Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo." Cell Mol Immunol 18(3): 773-775.
  15. Xia, C., T. Wang, H. Cheng, Y. Dong, Q. Weng, G. Sun, P. Zhou, K. Wang, X. Liu, Y. Geng, S. Ma, S. Hao, L. Xu, Y. Guan, J. Du, X. Du, Y. Li, X. Zhu, Y. Shi, S. Xu, D. Wang, T. Cheng and J. Wang (2020). "Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment." Leukemia 34(9): 2375-2383.
  16. Guo, R., F. Hu, Q. Weng, C. Lv, H. Wu, L. Liu, Z. Li, Y. Zeng, Z. Bai, M. Zhang, Y. Liu, X. Liu, C. Xia, T. Wang, P. Zhou, K. Wang, Y. Dong, Y. Luo, X. Zhang, Y. Guan, Y. Geng, J. Du, Y. Li, Y. Lan, J. Chen, B. Liu and J. Wang (2020). "Guiding T lymphopoiesis from pluripotent stem cells by defined transcription factors." Cell Res 30(1): 21-33.
  17. Guo, R., H. Wu, J. Du and J. Wang (2020). "T cell regeneration: an update on progress and challenges." Blood Sci 2(1): 22-26.
  18. Hu, F., D. Huang, Y. Luo, P. Zhou, C. Lv, K. Wang, Q. Weng, X. Liu, Y. Guan, Y. Geng, J. Du, J. Chen, J. Wang and H. Wu (2020). "Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells." J Immunother Cancer 8(2).
  19. Wang, T., C. Lv, F. Hu, L. Liu and J. Wang (2020). "Two-step protocol for regeneration of immunocompetent T cells from mouse pluripotent stem cells." Blood Sci 2(3): 79-88.
  20. Dong, Y., K. Wang, Q. Weng, T. Wang, P. Zhou, X. Liu, Y. Geng, L. Liu, H. Wu, J. Wang and J. Du (2020). "NUP98-HOXA10hd fusion protein sustains multi-lineage haematopoiesis of lineage-committed progenitors in transplant setting." Cell Prolif 53(9): e12885.
  21. Zhang, M., Y. Dong, F. Hu, D. Yang, Q. Zhao, C. Lv, Y. Wang, C. Xia, Q. Weng, X. Liu, C. Li, P. Zhou, T. Wang, Y. Guan, R. Guo, L. Liu, Y. Geng, H. Wu, J. Du, Z. Hu, S. Xu, J. Chen, A. He, B. Liu, D. Wang, Y. G. Yang and J. Wang (2018). "Transcription factor Hoxb5 reprograms B cells into functional T lymphocytes." Nat Immunol 19(3): 279-290.
  22. Weng, Q., F. Hu, M. Zhang, Y. Dong, C. Lv, Y. Wang, X. Liu and J. Wang (2018). "A protocol for generating induced T cells by reprogramming B cells in vivo." Cell Regen 7(1): 7-15.
  23. Wang, T., C. Xia, Y. Dong, X. Chen, J. Wang and J. Du (2018). "Trim27 confers myeloid hematopoiesis competitiveness by up-regulating myeloid master genes." J Leukoc Biol 104(4): 799-809.
  24. Li, X., C. Xia, T. Wang, L. Liu, Q. Zhao, D. Yang, F. Hu, M. Zhang, K. Huang, Y. Geng, Y. Zheng, Y. Guan, H. Wu, X. Chen, G. Pan, J. Chen, J. Du and J. Wang (2017). "Pyrimidoindole derivative UM171 enhances derivation of hematopoietic progenitor cells from human pluripotent stem cells." Stem Cell Res 21: 32-39.
  25. Wang, T., C. Li, C. Xia, Y. Dong, D. Yang, Y. Geng, J. Cai, J. Zhang, X. Zhang and J. Wang (2015). "Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo." Am J Transl Res 7(10): 1963-1973.
  26. Chen, X., Q. Zhao, C. Li, Y. Geng, K. Huang, J. Zhang, X. Wang, J. Yang, T. Wang, C. Xia, X. Liu, M. Meng, D. Yang, Y. Zheng, J. Du, X. Zhang, J. Chen, G. Pan and J. Wang (2015). "OP9-Lhx2 stromal cells facilitate derivation of hematopoietic progenitors both in vitro and in vivo." Stem Cell Res 15(2): 395-402.
  27. Yang, D., X. Zhang, Y. Dong, X. Liu, T. Wang, X. Wang, Y. Geng, S. Fang, Y. Zheng, X. Chen, J. Chen, G. Pan and J. Wang (2015). "Enforced expression of Hoxa5 in haematopoietic stem cells leads to aberrant erythropoiesis in vivo." Cell Cycle 14(4): 612-620.
  28. Wang, J., G. Kong, Y. Liu, J. Du, Y. I. Chang, S. R. Tey, X. Zhang, E. A. Ranheim, M. K. Saba-El-Leil, S. Meloche, A. Damnernsawad, J. Zhang and J. Zhang (2013). "Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions." Blood 121(26): 5203-5207.
  29. Wang, J., Y. Liu, Z. Li, Z. Wang, L. X. Tan, M. J. Ryu, B. Meline, J. Du, K. H. Young, E. Ranheim, Q. Chang and J. Zhang (2011). "Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner." Blood 118(2): 368-379.
  30. Wang, J., Y. Liu, Z. Li, J. Du, M. J. Ryu, P. R. Taylor, M. D. Fleming, K. H. Young, H. Pitot and J. Zhang (2010). "Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia." Blood 116(26): 5991-6002.